Evaluation and Comparison of Keloids and Second Degree Burns Blisters Fluid
It is well documented that following thermal burns injury the development of hypertrophic scars and keloid (HSK) ranges between 40 to 90%. on the other hand It is well documented that cryosurgery wounds generally heal with minimal tissue contraction, resulting in good cosmetic results and with minimal complications.
The Aim of the study is To specify the burn and cryosurgery blister fluid for proteins, cytokines and cells and To compare between the above data regarding possible proteins, cytokines and cells, in regard to their possible effect on scarring and wound healing.
Also to Identify those components which are present only in the cryosurgery blister and which might have an anti-scarring effect and to characterize them biochemically.
Second Degree Burns
|Study Design:||Time Perspective: Cross-Sectional|
|Official Title:||Comparison of the Blister Fluid Components of Second Degree Burned Patients With the Blister Fluid Components Following Intralesional Cryosurgery of Keloid Scars - A Feasibility Study.|
- comparison of inflamation cells and proteins (proteomic evaluation) between blisters caused by heat and blisters caused by cryo injury [ Time Frame: at time of sampling. ] [ Designated as safety issue: No ]
the protein evaluation and comparison is achieved by the use of proteomic study which evaluate the quantity of about 700 different proteins in the fluid of the different blisters (heat blisters compared to "cryo" blisters).
we also evaluate the differences in quntities between the inflamation cells in each sample.
Biospecimen Retention: Samples With DNA
blister fluid of kryosurgery and second degree burns
|Study Start Date:||July 2012|
|Estimated Study Completion Date:||July 2013|
|Estimated Primary Completion Date:||June 2013 (Final data collection date for primary outcome measure)|
second degree blisters patients
blister fluids of second degree burns
blister fluids of cryosurgery wounds
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01627769
|Contact: yaron har-shai, Mdfirstname.lastname@example.org|
|Contact: nir gal or, Mdemail@example.com|
|Carmel Medical Center||Recruiting|
|Contact: yaron har-shai, Md 050-7866206 firstname.lastname@example.org|
|Contact: nir gal or, Md 054-5454636 email@example.com|
|Principal Investigator: yaron har-shai, Md|
|Principal Investigator:||yaron har-shai, Md||carmel medical center- ISRAEL|